USC earns award of excellence see more
In recognition of their dedication and innovations in overcoming the challenges of delivering the experiential curriculum during the past year, the American Association of Colleges of Pharmacy Experiential Education Section has bestowed the Award for Excellence in Experiential Education upon the faculty and staff of experiential offices at the colleges and schools of pharmacy, including the University of South Carolina College of Pharmacy.
The Experiential Education team of Jennifer Baker, director of experiential programs; Whitney Maxwell, associate director of experiential programs; Kathryn Kenard, student service program coordinator; and Nancy Blaisdell, administrative assistant, received certificates of recognition from the AACP during a presentation by Julie Sease, interim dean of the College of Pharmacy.
The AACP Experiential Education Section Award of Excellence in Experiential Education is normally presented each year to an individual, but this year, the organization chose to recognize programs across the country.
When the University closed in March 2020, the Office of Experiential Education for the College of Pharmacy mobilized to a virtual unit overnight as there could be no pause in operations to keep students progressing through the Pharm.D. curriculum. With the status of hundreds of rotations changing on what seemed like an hourly basis during the spring and summer of 2020, Baker and Maxwell navigated rotation rescheduling while Kenard and Blaisdell tirelessly worked through site onboarding requirements to efficiently move students on and off rotation without missing a beat.
“Through the hard work and commitment of our preceptors and practice sites, we were able to successfully graduate the Classes of 2020 and 2021 on time,” says Baker. “Our team was dedicated to our students even while serving on the front lines of the battle against COVID-19. While our experiences were not unique, as everyone’s worlds were turned upside down during the pandemic, I can confidently say that our students and College are blessed with the best preceptors and faculty.
“We are so grateful for the unwavering support from College administration and for this recognition by the AACP Experiential Education Section. It was incredible to see the collaboration that occurred within our profession at the local, state and national level to support all pharmacy students.”
7 years in a row for MUSC see more
MUSC Health University Medical Center in Charleston was named by U.S. News & World Report for the seventh year in a row as the No. 1 hospital in South Carolina, with three of MUSC Health’s specialty areas ranking among the best in the entire country: ear, nose and throat; gynecology and cancer.
Seventeen other MUSC Health programs are considered “high performing” specialties, procedures or conditions in the 2021-2022 U.S. News & World Report rankings: gastroenterology and GI surgery, abdominal aortic aneurysm repair, aortic valve surgery, heart attack, heart bypass surgery, heart failure, back surgery (spinal fusion), hip replacement, kidney failure, chronic obstructive pulmonary disease (COPD), lung cancer surgery, pneumonia, stroke, colon cancer surgery, rheumatology, orthopedics and urology.
In addition, MUSC Health Florence Medical Center is designated as “high performing” in chronic obstructive pulmonary disease (COPD), heart failure, heart attack and kidney failure.
“Once again, South Carolinians can take great pride and comfort in the knowledge that their only public, statewide hospital system is consistently cited as one of the best in the country,” said Patrick J. Cawley, M.D., MUSC Health CEO and MUSC vice president for Health Affairs, University. “It’s a transformational time in health care and these rankings are a testament to our care team’s commitment to ensure that our patients are receiving the right care, in the right place and at the right time. The achievements in our Charleston and Florence divisions made despite the pandemic should remind us all what’s possible through innovation, teamwork, and growth.”
U.S. News & World Report unveiled the 32th edition of the Best Hospitals rankings at https://health.usnews.com/best-hospitals/rankings. Designed to help patients with life-threatening or rare conditions identify hospitals that excel in treating the most difficult cases, Best Hospitals 2021-22 includes consumer-friendly data and information on 4,750 medical centers nationwide in 15 specialties and 17 procedures and conditions. In the 15 specialty areas, 175 hospitals were ranked in at least one specialty. In rankings by state and metro area, U.S. News & World Report recognized hospitals as high performing across multiple areas of care.
“I am so proud that U.S. News & World Report has recognized MUSC Health Florence Medical Center as high performing in four areas – chronic obstructive pulmonary disease (COPD), heart failure, heart attack and kidney failure,” said Jay Hinesley, MUSC Health Florence Division CEO. “The last year has been a challenge for everyone in health care, and these recognitions are a true testament to all the hard work of our care team members and their dedication to our patients, families and communities. We are committed to continuing to preserve and optimize human life in South Carolina and beyond.”
The U.S. News & World Report Best Hospitals methodologies, in most areas of care, are based largely or entirely on objective measures such as risk-adjusted survival and readmission rates, volume, patient experience, patient safety and quality of nursing, among other care-related indicators.
1. - U.S. News & World Report’s produced Best Hospitals with RTI International, a leading research organization based in Research Triangle Park, N.C.
Life sciences booming in Spartanburg, Upstate see more
Spartanburg County – and the entire Upstate – are welcoming a growing interest and investments from life sciences companies. The Upstate has a long-established history and infrastructure that have supported life sciences companies with raw materials, production and packaging operations, and distribution.
Now, new research and innovation businesses are further supporting industry growth and fueling an ecosystem ripe for start-ups.
More than 670 life sciences firms of all sizes call the Upstate home, with 13 companies announcing new locations in the area in the last few years.
The newest of those companies in Spartanburg is Epica International, the leader in advanced, ultra-high-resolution mobile medical imaging and robotic applications for human and animal health, and industrial enterprises.
The company announced its headquarters and operations in Spartanburg, covering its subsidiary companies Epica Human Health, Epica Animal Health and Roboticom. Epica established corporate, imaging and robotic system demos at its facility, currently located inside the Spark Center SC on the Tyger River Campus of Spartanburg Community College.
“Epica’s investment in Spartanburg goes hand-in-hand with a diversified economic development strategy we’ve put in place countywide, targeting specifically investments from bioscience and life sciences industries,” said OneSpartanburg, Inc. Chief Economic Development Officer Katherine O’Neill. “These types of advanced, heavy-technology industries coming to our county gives us a considerable strategic advantage for future development and job growth.”
Another life sciences company – Pall Corporation – announced its intent to invest in Spartanburg County earlier in 2021. Pall announced its Spartanburg County operations would create 425 new jobs and $30.2 million in investment.
Pall serves the needs of customers across the broad spectrum of life sciences and industry and works with clients around the world to advance health, safety and environmentally responsible technologies. The company’s Spartanburg facility supports the rapid development of vaccines and therapeutics, including COVID-19 vaccines.
"Spartanburg County provides Pall with the diverse workforce we need to manufacture life-saving therapeutics and vaccines. We look forward to building our presence in this county,” said Pall Life Sciences President Joseph Repp at the time of the company’s announcement.
Statewide, South Carolina has a significant presence in the medical device sector. And the manufacturing supply chain is robust when it comes to life sciences, mirroring the strength of the area’s overall manufacturing prowess.
From 2015-2019, medical devices and equipment companies added 35% more jobs and accounted for 11.5% of the new companies coming to the Upstate. And on top of that, more than 700 clinical trials are being undertaken across the Upstate at any given time in the fields of oncology, companion diagnostics, genetics and more.
The Upstate in particular has a network of acclaimed hospitals, technical training schools and more than 26 colleges and universities actively working with industry leaders and educators on all levels to ensure access a highly-skilled workforce for decades to come.
“Spartanburg’s historic advantages when it comes to infrastructure, distribution capabilities and even the county’s location, make it a favorable home for continued investments from biosciences and life science industries,” said O’Neill. “That positions us well for the future as these industries continue to bring higher-wage, knowledge-based jobs to Spartanburg.”
Issues over $3 million in funds to colleges, universities see more
SCRA has announced the funding of over $3.3 million to selected colleges and universities for translational research projects to address key challenges facing the state’s industrial base. SCRA’s funding is being matched by the academic institutions and industry partners, bringing the total amount of the projects to over $6.7 million.
The projects are being funded through the SCRA-Academia Collaboration Team (SACT) program. The goal of the SACT is to connect industry with multi-institutional academic teams and build bridges among the institutions to foster engagement and advance technologies, many of which will enter the marketplace and lead to the creation of South Carolina-based jobs.
- $1.8 million was awarded to Clemson University to modernize South Carolina’s manufacturing assets to enable Industry 4.0 (the ongoing automation of traditional manufacturing and industrial practices, using modern smart technology). Clemson is partnering with the University of South Carolina, the Medical University of South Carolina, South Carolina State University, Greenville Technical College, and Trident Technical College.
- $1.2 million was awarded to the University of South Carolina to enable factory-to-factory networking for the future of manufacturing operations. The University is partnering with Clemson University, Greenville Technical College, and Midlands Technical College.
- $305,000 was awarded to Francis Marion University to improve workforce readiness and capabilities in South Carolina. The University is partnering with The Citadel.
“I’m energized by the opportunities and positive outcomes from this intersection of academic research, entrepreneurship, and industry in the state. These collaborations provide the greatest potential for innovation, economic growth, and overall advancement of the region,” said Kella Player, SCRA Program Manager.
SCRA’s program directors and industry advisors will review the progress on these SACT research projects on an ongoing basis. Funds will be provided in stages as milestones are met.
“We are fortunate to have high-quality research and development being conducted at our state’s colleges and universities. Many of the technologies on which they are working today will produce the new companies of tomorrow. It’s a honor for SCRA to support these collaborations,” said Bob Quinn, SCRA Executive Director.
Since 2018, SACT grants have funded 17 collaborations among South Carolina-based academic institutions and 41 industry partners. These projects have produced an 8:1 multiple in additional funding from other sources such as industry and the federal government.
SCRA grants are funded in part by the Industry Partnership Fund (IPF). IPF contributors are South Carolina businesses and individuals who receive a dollar-for-dollar state tax credit for investing in the state’s innovation economy.
Helping patients stay out of hospital, recover faster see more
Prisma Health is taking key elements of inpatient care into patients’ homes to help them stay out of the hospital under a new program for the Midlands called Home Recovery Care.
The model has been used at Prisma Health hospitals in the Upstate, according to a news release.
For patients under care through Prisma Health Richland Hospital, the organization partners with Nashville, Tenn.-based Contessa to deliver the service at its third site, the news release said.
The program launched at Greenville Memorial Hospital in 2019 and expanded to Oconee Memorial Hospital last year. In the Upstate, the program has a 90% acceptance rate and an average patient satisfaction score of 98%, according to the release.
Prisma Health was one of the first health systems approved to provide Home Recovery Care to Medicare fee-for-service patients under the Center for Medicare and Medicaid Services’ Hospitals Without Walls waiver, the release said. Programs that encourage hospitals to find healthy ways to stay out of emergency rooms and hospital rooms have been part of Medicare/Medicaid rules for years, with the COVID-19 pandemic spurring more efforts.
“Prisma Health has had great success with the program in the Upstate, and we are thrilled to provide this level of home care to more South Carolinians by adding it at Richland,” Bo Cofield, Prisma Health Richland Hospital CEO, said in the release. “The COVID-19 pandemic reinforced that going beyond the walls of the traditional hospital setting often gives our patients a better option for acute-level health care. Home Recovery Care was in place before the pandemic, but it is now gaining momentum. We believe this kind of service is essential to the care of our patients and is an important component of health care.”
Home recovery is more satisfying for patients and costs less than traditional recovery in a hospital, according to the release.
The care is for patients with acute, non-life-threatening medical conditions. Roughly 150 diagnoses are considered eligible for the service and range from congestive heart failure and pneumonia to dehydration, cellulitis and urinary tract infections. Patients must be evaluated by a Prisma Health doctor to determine if their conditions can be safely treated in the home instead of a standard hospital environment, according to the release.
The program includes 24-hour access to a recovery care coordinator and continual monitoring for up to 30 days, the release said. The in-home work is done by Prisma Health’s home-health registered nurses and by physician consultation utilizing telehealth.
“Since we launched the program, we have served 300 patients and saved patients from being hospitalized for 1,000 additional inpatient days,” Angela Orsky, vice president of post-acute services at Prisma Health, said in the release. “Our patient likelihood to recommend scores are 100, and we are exceeding all our quality targets. Our home health clinicians in partnership with our hospitalists have exceled in the ability to care for complex patients safely in their homes.”
PMLS donates rapid antigen tests to Diabetes Education camps see more
Premier Medical Laboratory Services donates rapid antigen tests to Diabetes Education and Camping Association Camps
Many children with diabetes look forward to summer camp each year to, not only spend time with friends, but with other children who can relate to similar day-to-day obstacles that living with diabetes can present. The Diabetes Education and Camping Association (DECA) unites the global diabetes camping community, providing leadership, education, and resources to make camps for those with diabetes more impactful. As most summer camps across the US resumed this year, diabetes camps were faced with the extraordinary obstacle of protecting children who are at higher risk for COVID-19 complications due to diabetes. To bring summer camps for children living with diabetes back this year and to help protect these children, one of the nation’s largest laboratories, Premier Medical Laboratory Services, donated thousands of COVID-19 tests to DECA camps in 19 states across the nation, enabling them to safely return to camp this year.
“We know DECA and each of their camps do so much for the diabetes community - helping kids to learn how to manage the disease as well as support emotional wellbeing,” said Kevin Murdock, Founder and CEO of PMLS. “With diabetes being a global pandemic, it’s a large focus for Premier Medical Laboratory Services to provide top healthcare solutions for patients with diabetes. We are honored to help camps that improve the lives of children and adolescents with diabetes.”
For some children, a diabetes camp is their first opportunity to meet a friend who also has diabetes, or their first time staying somewhere without their parents. It’s a great place for them to adopt a new hobby or learn skills that give them more self-confidence. Along with the feeling of independence and support, diabetes camps have been shown to provide children with an increase in diabetes self-care abilities and decreased diabetes-specific distress. (1) For caregivers, diabetes camps provide a medically sound environment where they can feel assured that their children are safe and their diabetes care needs are met.
Terry Ackley, Executive Director of DECA added: “The safety of children with diabetes is the highest priority of diabetes camps. Covid-19 has presented significant challenges to the operation of diabetes camps this year. It has required that they carefully study their program delivery model and incorporate additional health and safety protocols following the newest guidelines from the Centers for Disease Control. A tool that is very important to safely serving children with diabetes at camp is Covid-19 testing. Premier Medical Laboratory Services approached the diabetes camping community to offer their much-needed support. Our community greatly appreciates their generous donation of a large quantity of rapid antigen tests to diabetes camps across the United States. Premier Medical Laboratory Services has been instrumental to the ability of diabetes camps to operate this year. Their support is helping children learn more about how to manage their diabetes, build resilience to living with this difficult health condition, develop cherished friendships and have lots of fun!”
Aside from offering COVID-19 testing and many other medical diagnostics solutions, PMLS is continually searching for innovative diabetes prevention and maintenance applications. With some of the most advanced testing panels for both type 1 and type 2 diabetes, PMLS also introduced to the US a first of its kind predictive genetic test for type 2 diabetes, which allows patients to know their risk of future onset of the disease determined by their individual genetic make-up. Along with this, Premier Medical Laboratory Services is currently working with the Juvenile Diabetes Research Foundation on initiatives to bring soccer clinics to diabetes communities as part of their mission to improve patient lives both medically and through community outreach. PMLS is soon to announce more breakthrough solutions for diabetes care.
For more information on Premier Medical Laboratory Services, please visit www.premedinc.com or call 866-387-2909.
South Carolina-based firm names new head of pharma and medtech see more
DUNCAN, SC - Stäubli announced today that Olivier Cremoux has been appointed Deputy Head of Pharma and Medical Device for Stäubli Robotics North America.
Cremoux joined Stäubli Group in 2015 before transferring to Stäubli Corporation as the North American Business Development Manager for Robotics in 2018. Most recently, he became Key Account Manager – Pharma and will maintain this role throughout the transition period. Cremoux will use his experience to help build the Medical Robotics team while focusing on the Pharma and Medical Device specific markets.
Cremoux graduated from the National Institute of Science Applied of Lyon (France) with a bachelor degree in Electrical Engineering.
Commenting on the announcement, North American Robotics Division Manager, Sebastien Schmitt stated, “We are pleased to announce Mr. Cremoux as Stäubli Robotics North American Deputy Head of Pharma and Medical Device. We believe Mr. Cremoux is the right leader for Pharma and Medical Device as we continue to expand our growing team. This is an important step in setting up an organization fully dedicated to the pharmaceutical industry to build on our existing expertise in a number of high‑tech markets.”
Olivier Cremoux: “I am honored by such an opportunity within Stäubli Robotics. The Pharma and Medical Device is a strategic and growing market in which Stäubli has provided, for over 20 years, significant technological innovations. High throughput screening, aseptic fill/finish, orthopedic surgery, bio-printing and cell culturing are examples of processes where Stäubli Robotics started as a pioneer and became a reference. With COVID-19 pandemic, robotics became even more essential to our customers, from drug production to Covid test manufacturing. In North America, we will continue the development of our organization to ensure all current and future needs of our customers.”
About Stäubli Robotics
Stäubli Robotics is a leading global player in robotics, consistently delivering engineering as effective and reliable as our service and support. A complete solutions provider for digitally networked production, Stäubli offers a broad range of 4- and 6-axis robots including robotic arms designed specifically for sensitive environments, autonomous mobile robots, driver-less transport systems (AGVs) and cobots for human-robot collaboration. www.Stäubli.com/robotics
About Stäubli North America
Stäubli North America has more than 200 employees supporting Connectors, Robotics and Textiles customers. The company’s North American headquarters is in Duncan, South Carolina. Stäubli provides customer support through its locations in Duncan, Queretaro, Mexico, and the newest Stäubli North American facility, which opened in 2018 in Novi, Michigan. In addition to 24/7 customer support, each of these facilities offers training and has dedicated on-site technical experts who can be deployed whenever needed. Stäubli’s North American sales force is located strategically on the West and East coasts, and also serves Canada and Puerto Rico.
Worldwide, Stäubli is a leading manufacturer of quick release couplings, robotics systems and textile machinery. With a workforce of more than 5,500 employees, Stäubli is present in 29 countries supported by a comprehensive distribution network in 50 countries worldwide.
Lou Kennedy and Nephron Team step up for SC again see more
Glove Plant Will Shore Up Domestic Supply Chain, Reduce American Dependence on Foreign Sources of Medical-Grade Gloves & Create New Jobs
WEST COLUMBIA, S.C. – During a celebration attended by strategic partners, business leaders and public officials, Nephron Pharmaceuticals Corporation CEO Lou Kennedy and Governor Henry McMaster today announced the opening of Nephron Nitrile, a plant that will produce American-made, medical-grade nitrile gloves.
The announcement is the latest Nephron expansion on the sprawling company campus located at Saxe-Gotha Industrial Park in Lexington County.
Nephron Nitrile – which will be headquartered in more than 400,000 square feet of space in the Kennedy Innovation Complex – represents an investment of more than $100 million in the Midlands. The plant will generate 250 jobs for the area.
“This is a historic day for our company, and, we believe, for South Carolina,” said Kennedy. “Over the course of the last year, we have poured every bit of creativity, energy and resources we have at our disposal into doing our part, as a proud Made-in-America manufacturer, to respond to an unprecedented crisis. Nephron Nitrile is the latest part of our ongoing effort to make South Carolina the nationwide example for effectively responding to America’s needs, this time by shoring up the domestic supply chain.”
Kennedy and the governor, along with the entire Nephron team, have made reducing the American dependence on foreign sources of critical health care-related items, such as personal protective equipment (PPE) and lifesaving medications, a top priority. Kennedy joined the governor in April when he announced an executive order to safeguard South Carolina from supply chain disruptions, such as those caused by countries like China, experienced during the COVID-19 pandemic by working to manufacture even more essential, life-saving products in South Carolina.
Now, just months later, Kennedy and her team at Nephron are stepping up once again. In doing the work on the front end of the announcement to secure partnerships with trusted companies to provide raw materials, machinery and technology, Nephron is in position to make a significant difference in bolstering the PPE supply chain by early 2022.
“It is critical that South Carolina lead the charge in bringing the production of life-saving medications and supplies back home to the United States,” said Governor McMaster. “After last year’s supply chain disruptions caused by the COVID-19 pandemic, I announced a new initiative aimed at expanding recruitment efforts of pharmaceutical and medical supply manufacturers in the Palmetto State. Nephron Pharmaceuticals Corporation’s continued investment in South Carolina and our people will go a long way toward creating much-needed independence in this industry. This great company continues to show that we have the talent and the ability to do anything we put our minds to, right here in South Carolina.”
Last July, Kennedy announced an investment of $215 million for Lexington County, bringing 380 new full-time jobs to the area by 2024, and adding new office, warehouse and vaccine production space. This announcement included the establishment of the Kennedy Innovation Complex, home of Nephron Nitrile, and these projects are ahead of schedule. Since re-locating company headquarters to Lexington County from Orlando, Nephron has invested more than a half billion dollars in the region, creating almost 2,000 full and part time jobs.
“Lexington County is beyond excited to say congratulations again to Nephron Pharmaceuticals,” said Lexington County Council Chairman M. Todd Cullum. “The county is enthusiastic about this announcement as much or more than the company’s original announcement to locate in Lexington County. Their investment in hard assets and jobs is second to none in South Carolina. Nephron’s partnership with Lexington County has been tremendous in helping to improve the quality of life in our county and the region. We can’t wait to see what the future holds for this extraordinary company.”
A West Columbia, S.C.-based company, Nephron develops and produces safe, affordable generic inhalation solutions and suspension products. The company also operates an industry-leading 503B Outsourcing Facility division which produces pre-filled sterile syringes, luer-lock vials, IV bottles and IV bags for hospitals across America, in an effort to alleviate drug shortage needs. Nephron launched a CLIA-certified diagnostics lab last year where it tests people for COVID-19 and administers vaccinations.
For more information regarding Nephron Nitrile, including orders and partnerships, please email: NephronNitrile@nephronpharm.com.
More than 43,500 women are expected to die from breast cancer in 2021 see more
A Clemson University study could lead to new immunotherapy for breast cancer. The study, according to the university, provides the foundation of using cells in our bodies to target cancer cells.
Clemson researchers have used the immune system’s natural killer cells — which the body uses to fight off certain types of infections — to go after the breast cancer cells by bridging the two cells with a fusion of proteins the researchers developed.
“The idea is to use this bifunctional protein to bridge the natural killer cells and breast cancer tumor cells,” said Yanzhang “Charlie” Wei, a professor in the College of Science’s Department of Biological Sciences. “If the two cells are brought close enough together through this receptor ligand connection, the natural killer cells can release what I call killing machinery to have the tumor cells killed.”
Breast cancer kills 43,000 women each year in the U.S., according to the American Cancer Society and one in eight women and one in 1,000 men will develop invasive breast cancer.
“Very simply, cancer is uncontrolled cell growth. Some cells will become abnormal and have the potential to become cancer,” Wei explained. “The immune system can recognize these abnormal cells and destroy them before they become cancer cells. Unfortunately for those who develop cancer, the immune system is not working very well because of gene mutations and environmental factors. The result is that the cancer cells won the fight between the immune system and the tumors.”
Clemson’s researchers focused on triple-negative breast cancer, the most lethal type of breast cancer, and prolactin receptors.
Goal to develop innovative products focused on improving the health of state residents see more
The Medical University of South Carolina’s Department of Surgery Human-Centered Design Program and The Citadel Tommy and Victoria Baker School of Business Innovation Lab will collaborate on a joint effort.
The program will create a core team of medical students, residents and Citadel cadets and students who will develop innovative products focused on improving the health of state residents, MUSC said in a news release.
Both programs similarly promote innovative thinking. The BSB Innovation Lab focuses on teaching students the value of ground-breaking thinking and offers then the chance and guidance to invent and helm business ideas, build out a business plan and pitch ideas to investors.
MUSC’s HCD program was founded to develop original ways to solve unmet surgical and medical needs. The program is led by Joshua Kim and was established under the leadership of chief of surgical oncology Dr. David Mahvi and vice chair of research Michael Yost, Ph.D.
The two programs were brought together in March 2020 when the country faced protective mask shortages, particularly N-95 versions, as the pandemic picked up pace.
During that time, Kim’s team of biomedical engineers and medical professionals developed plans for 3D-printed masks. The BSB Innovation Lab then collaborated with MUSC to print more than 500 masks to help to resolve the region’s shortage.
“Through this new partnership, we can seamlessly innovate a design, develop a business plan and produce products that improve patient care,” said Mahvi.
By coming together, the partnership promotes collaboration, academic growth and learning opportunities students may not have experienced in their respective schools. Residents and medical students are immersed in business training and entrepreneurship skills, while business students are exposed to the health care system.
By working together, Capt. James Bezjian, director of the Innovation Lab and an assistant professor of strategy and entrepreneurship in the Baker School of Business, said the schools are able to work on projects that have “life-changing” capabilities.
“The relationship the BSB Innovation Lab built with MUSC during the height of the pandemic provided an opportunity for us to partner and continue working toward improving the lives of medical professionals and the patients they take care of,” Bezjian said.
BridgeBio Pharma Announces Collaboration with MUSC Foundation for Research Development, 2 Other Research InstitutionsWill identify and advance therapies for genetic diseases and cancers see more
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today announced three new academic collaborations with MUSC Foundation for Research Development, Stanford University and the University of Pittsburgh (Pitt) to translate cutting-edge discoveries into potential therapies for patients with genetic diseases and genetically driven cancers.
"The chance to partner with exceptional researchers at the Medical University of South Carolina, Stanford University and University of Pittsburgh is a privilege, and we believe will help us advance our mission to discover, create, test and deliver life-changing medicines for patients in need as rapidly as possible," said BridgeBio founder and CEO Neil Kumar, Ph.D.
To date, BridgeBio has worked with 23 leading institutions throughout the country that are focused on providing treatment options to patients as quickly and safely as possible. For a list of some of the institutions BridgeBio is partnered with, please visit Our Partners page.
MUSC Foundation for Research Development
MUSC Foundation for Research Development provides technology transfer services to Medical University of South Carolina (MUSC), which is a patient-centric research institution with several hospitals in South Carolina and is considered the state's top healthcare provider. MUSC's innovative and high-quality research will allow for early identification of research programs with a strong potential to be beneficial for patients. Through this partnership, BridgeBio may sponsor research programs and support the development of identified programs toward potential clinical investigation through its licensing and affiliate development model.
"Like BridgeBio, we have a patients first mentality, so partnering together on early research will be an excellent opportunity to advance our innovation in the hope of generating new therapies for patients," said Scott Davis, Ph.D., senior director of innovation support and commercialization of MUSC Foundation for Research Development.
About BridgeBio Pharma, Inc.
BridgeBio Pharma (BridgeBio) is a biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio's pipeline of over 30 development programs ranges from early science to advanced clinical trials and its commercial organization is focused on delivering the company's first two approved therapies. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com.
Aptus Life Receives $25,000 from the Emerson Rose Heart Foundation to Develop a Living Heart Valve ReplacementGrant will fund the initial prototyping of a living heart valve replacement see more
Aptus Life, LLC announced today that it secured a $25,000 grant from the Emerson Rose Heart Foundation (ERHF) of Clemson, SC. Aptus Life’s objective is to develop a replacement heart valve for infants, children, and young adults that would last their entire lifetime without the need for blood thinning medication or additional valve replacement procedures. This aligns with ERHF’s mission “to change the future for those affected by congenital heart defects by providing support to families in need, advancing patient care and medical research, and increasing awareness about the most common birth defect in the world.”
"A living heart valve replacement is bound to revolutionize the field of translational regenerative medicine and improve the quality of life of thousands of patients. It would shift clinical practices toward permanent solutions instead of temporary stopgaps," said Lee Sierad, CEO of Aptus Life.
While significant strides have been made in the development of heart valve replacements for adults, the infant to young adult population is currently underserved. Current valves used for infants and young adults require geometry modification, life-long medication, and follow-on operations to replace valves that fail or that they outgrow. In response, Aptus life envisions a clinical scenario whereby fat tissue is collected from the patient, cells are prepared and seeded onto a biological scaffold, and a living, patient-specific heart valve made from the patient’s own cells is implanted back into the patient. This living heart valve can then serve as a single, lifelong solution that minimizes the risks and costs associated with traditional valve replacements.
Aptus Life is in the early stage of developing a living valve replacement. The company has secured the cell collection and preparation methods as well as the valve testing equipment. They are now focusing on the biomaterial scaffold, cell seeding, and valve assembly methods. Funding from the Emerson Rose Heart Foundation will propel this research into the next stage of development: the formation and testing of numerous valve prototypes.
As one member of the Aptus Life team said: “Having the support of such a loving and inspiring organization has given us the drive we need to push this project along. While $25,000 will significantly assist us in our financial needs, it is the Emerson Rose heart Foundation’s profound faith and support that will assist us in translating this research into a viable, lifelong solution for patients worldwide.”
About Aptus Life, LLC
Aptus Life is a privately-held, regenerative medicine company focused on developing a living heart valve replacement that utilizes a patient’s own cells to grow and regenerate for their entire lifetime. This product will dramatically improve the quality of life outcomes for those children and young adults who currently face future revision operations or lifelong anticoagulation medication. For more information, visit www.AptusLife.com.
About the Emerson Rose Heart Foundation
The mission of the Emerson Rose Heart Foundation is to change the future for those affected by congenital heart defects by providing support to families in need, advancing patient care and medical research and increasing awareness about the most common birth defect in the world. Our ultimate purpose through these efforts is to share the love and hope of Jesus Christ. We are a 501(c)(3) tax-exempt organization and serve an average of 350 families each year with funding solely from individuals, the community, and corporate contributions with no federal or state funding. For more information, visit www.EmersonRoseHeartFoundation.org.
Columbia, SC company aims for growth see more
Compliments of SCBIZ News and Columbia Business Report
Columbia-based Rhino Medical Supply has been named the exclusive distributor of Deltapine cotton medical scrubs in an initiative created to drive demand for U.S.-grown cotton and revitalize an end-to-end U.S. supply chain.
The Field to Closet partnership with Nashville-based Jernigan Global, a consultancy for the cotton supply chain and textile industry, was created in 2019 to create awareness among producers, ginners, millers and retailers of advancements in U.S. upland cotton, specifically Deltapine Select varieties. Rhino will distribute the initiative’s 100% cotton scrubs made with Georgia-grown cotton through the initiative’s Cotton Project.
“We are thrilled to announce an alliance with Rhino Medical Supply as the distributor of our cotton scrubs,” Ed Jernigan, founder and CEO of Field to Closet, said in an online article by Cotton Grower magazine published Tuesday. “Rhino Medical’s focus on sustainable, environmentally friendly, and biodegradable products, along with their emphasis on philanthropy and diversity initiatives, pairs perfectly with our scrubs program. It is truly a perfect union of businesses with similar visions.”
The Cotton Project has also established a Farmer GiveBack program to ensure the grower shares in financial profits of goods sold.
“Rhino Medical Supply seeks companies and products that align with our corporate citizenship commitments, including giving back to others, using renewable resources, and encouraging inclusion,” Rhino CEO Lance Brown said. “Our organization is proud to work with Field to Closet and America Knits to distribute these 100% Deltapine cotton medical scrubs.”
The medical scrubs are treated with PROTX2 AV technology, a metal-free, medical grade anti-viral, anti-bacteria and anti-odor treatment that kills viruses and bacteria, including the virus that causes COVID-19, according to the article. Brown called the technology a “game changer” for the U.S. medical industry in its fight to prevent another pandemic outbreak.
“We are thrilled to partner with Field and Closet to introduce the first OR scrubs powered by PROTX2 AV technology,” Giancarlo Beevis, president and CEO of Intelligent Fabric Technologies North America, said. “This is a key step in breaking the chain of infection and provides healthcare professionals with a new line of defense in infection prevention.”
To launch the initiative, 15 rural Georgia hospitals will receive the scrubs at no cost this summer.
“Partnering with Rhino Medical Supply means our scrubs will be available to hospitals and other health care facilities from coast-to-coast,” said Steve Hawkins, president of America Knits. “This partnership matches perfectly with our focus on providing prosperity for rural, smaller communities and creating quality, environmentally sustainable products in the United States.”
Largest donation ever granted to university’s College of Science see more
Clemson graduate Emily Peek Wallace is giving back to her alma mater through the largest donation ever granted to the university’s College of Science: $1.25 million for an endowed directorship.
An endowed faculty position allows Clemson to retain top talent, according to a news release.
As the first endowed faculty position at the School of Mathematical and Statistical Sciences, the Emily Peek Wallace ’72 Endowed Directorship provides support for the school director and supports additional initiatives throughout the school.
“I wanted to do something to help the faculty,” Wallace said in the release. “Everybody has had to shift their teaching and learning methods due to COVID-19, and the faculty has additional challenges to make sure students are not getting behind and that they’re learning what they need to be learning. I wanted to provide encouragement and funding to help them, add additional facilities to help students stay current.”
The purpose of the endowment focuses on increasing student engagement and success, as well as enhancing the relevance of the curriculum for the next generation of mathematicians, statisticians and data scientists.
The support includes tutoring assistance for students who may be struggling academically or to help students who may have fallen behind due to unforeseen circumstances. Additionally, the funding will help establish business connections and internships for students who wish to enter the job force instead of going into academic research, and will make training with current statistical software and other resources available for students regardless of future tracks, according to the release.
“With gifts such as this one from Emily, our donors help position Clemson as a destination for the finest academic leaders to develop innovative curriculums benefitting our students and equipping them with the skills needed for what is to come,” Brian O’Rourke, vice president for development and alumni relations at Clemson, said in the release. “Our donors are investing in the future — not just in Clemson and our students, but also in the industries our students will influence. We can’t thank them enough for their assistance and generosity.”
Wallace was the first woman to serve as a top leader of the university’s WSBF radio station and was named to Who's Who Among Students in American Universities and Colleges. She was often the sole woman — or one of only two — in her technical courses. A first generation college graduate, she graduated with a Bachelor of Science in Mathematics in 1971.
In 2014, she established the Emily Peek Wallace ’72 Scholarship Endowment for STEM, which provides financial assistance for underrepresented students in science, technology, engineering and mathematics, according to the release. This academic year, 25 students will benefit from the Wallace scholarships. In addition to the two endowments, she also serves on the Clemson University Foundation Board of Directors and as a founding member of the Order of the Oak.
Wallace and her husband Jack were among the first 100 employees to join the Statistical Analysis System Institute in 1981. Headquartered in Cary, N.C., SAS is a global software company, which has also provided support to Clemson through software.
Currently, she oversees a team of 50 people as the senior director of the Knowledge Management Center at SAS.
“I am so honored to have met such special people within the Clemson family, like Emily Wallace,” Cynthia Young, dean of the College of Science, said in the release. “She was and remains a pioneer at SAS, paved the way and created opportunity for so many, including our Clemson students. Under the leadership of the Emily Peek Wallace ’72 Director, our outstanding faculty and staff will honor her legacy with their new discoveries, innovation, and in how they are preparing the next generation of leading mathematicians, statisticians and data scientists.”
USC College of Pharmacy hosts special event for minorities see more
The University of South Carolina’s College of Pharmacy held a COVID-19 vaccine education event at the Juneteenth Freedom Fest. Instructors and students from the college offered science-based information to passersby who had not been vaccinated yet.
DHEC data suggests that minorities make up approximately 43% of South Carolinians who have received at least one COVID-19 shot. Data from DHEC also shows that Black South Carolinians make up just 19.5% of people with at least one dose.
“We feel like we can do better,” said clinical associate instructor and infectious diseases pharmacy specialist Dr. Julie Ann Justo. “We want to protect individuals and their loved ones from contracting COVID-19.”
The college hosts similar community education events regarding various public health issues such as penicillin allergies and flu shots at events like Soda City Market. The program chose to host the COVID-19 vaccination information booth at the Juneteenth event to target specific groups that may be hesitant to get their shot.
“Juneteenth is the place to be this weekend; there’s a lot of joy here, a lot of celebration and remembrance and respect for history,” said Justo. “We’re really excited to be here with the community and listen to their concerns as they relate to COVID-19 vaccination, and hopefully give a little bit of helpful information as well.”
Dr. Justo says the pharmacy students that talked to community members are vaccine experts. She says they have been studying all vaccines for at least four years and they also have extensive knowledge about the COVID-19 vaccines.
Dr. Jordan Cooler, clinical assistant professor of pharmacy and psychiatric pharmacist, says she hopes the event helped the community understand both the vaccine and the role of pharmacists better. She says pharmacists are among the most accessible medical professionals as they typically don’t require appointments for consultations.
“This is an opportunity for our students to get out into the community and hone those skills, as far as educating individuals and interacting,” said Cooler. “We’re coming and we’re meeting them where they’re at.”
Cooler says the event served to boost vaccine confidence in the community and if people felt more confident getting their shot after speaking to the students, they were able to go get their shot at a vaccine tent that was also at the festival.
The college plans to continue educating the public in the coming weeks about the COVID-19 vaccine to help increase vaccination rates across the state.